Aqua Pharmaceuticals, LLC Appoints Ted White as COO, Mark Boyer as Director of Finance
News Feb 12, 2013
As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-command to the company’s President and CEO, Craig Ballaron.
“I can always depend on Ted to be ahead of the curve,” said Ballaron. “He’s a fantastic manager, and his combination of sales savvy and steadfast leadership have helped him move up quickly within the company.”
White joined Aqua in 2011 following a successful 21-year sales career with Novartis Pharmaceutical Corporation, where he led sales teams in new product launches and executed tactics for multiple billion-dollar brands. In July 2010, PharmaVoice magazine named him one of the top 100 inspirational leaders in the health sciences field.
As the new Director of Finance, Boyer, who is a licensed CPA, will manage the company’s budget and lay out operational fiscal policies.
“Having someone with a solid, analytical understanding of both numbers and the pharmaceutical industry in general is invaluable to Aqua,” said Ballaron. “As Controller, Mark demonstrated a knack for both. He’s adept at data analysis and managing corporate funds, so moving to the role of Director of Finance was a natural progression.”
Prior to joining Aqua in 2010, Boyer worked as a Senior Accountant for Teleflex Incorporated’s ARROW International division, where he was responsible for financial reporting, Sarbanes-Oxley compliance and fixed-asset management.
“This is a dynamic time of growth and change for Aqua,” said Ballaron. “I am excited to help write the next phase in our company’s history with Ted and Mark at my side.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
What Does the Future of Vaccines and Immunotherapy Look Like?News
Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.READ MORE